Coloplast's Impressive 9M 2024/25 Results Highlight Growth
Coloplast's Thriving Financial Performance for 9M 2024/25
Coloplast A/S has released its interim financial results for the nine months ending in 2024/25, signaling robust growth and strategic advancements. During this period, the company achieved organic growth of 7% while maintaining an impressive EBIT margin of 28% in the third quarter. Although reported revenue in Danish Kroner (DKK) increased by 1%, adverse currency movements and the divestment of the Skin Care segment had a dampening effect.
Business Area Performance Insights
The performance across various business segments was varied and telling of Coloplast's current market strategies. The organic growth rates broken down by segment include:
- Ostomy Care: 6% growth, driven by contributions from various regions, although China displayed low-single digit growth, aligning with forecasts.
- Continence Care: 8% growth attributed to the successful Luja™ product portfolio.
- Voice and Respiratory Care: 9% growth, benefiting from strong demand in both Laryngectomy and Tracheostomy.
- Advanced Wound Care: A decline of 2% was noted primarily due to a significant reduction in sales in China, linked to a proactive product recall of Biatain® Adhesive foam dressings.
- Interventional Urology: Stable growth driven by the success in the US Men’s Health segment, albeit slightly offset by ongoing issues arising from product recalls.
Financial Highlights and Projections
The EBIT for Coloplast was reported at DKK 1,915 million, translating to a 2% year-over-year increase. This growth has resulted in a sustaining EBIT margin of 28%. For the nine-month period, the total reported revenue increased by 4%, reaching DKK 20,914 million.
Coloplast’s outlook for the fiscal year remains consistent, aiming for organic growth around 7% and an EBIT margin positioned between 27% and 28%. Future projections do incorporate anticipated challenges such as the impact from product recalls in Advanced Wound Dressings in China, but these are largely counterbalanced by growth in other areas.
Leadership Changes and Strategic Vision
In light of its evolving strategy and goals toward 2030, Coloplast announced changes to its Executive Leadership Team to enhance its operational effectiveness. Interim CEO Lars Rasmussen addressed stakeholders by stating, "We deliver a third quarter as expected with 7% organic growth and an EBIT margin of 28%, maintaining our financial guidance for 2024/25. Our Q3 performance was driven by broad-based growth across our chronic care businesses, offsetting the challenges in China. I’m pleased to see the global Coloplast organisation continuing to deliver on our priorities and moving the business forward. The search for Coloplast’s new CEO remains on track. I look forward to presenting our 2030 strategy..."
The anticipated capital expenditures and tax rates remain unchanged, affirming Coloplast's steady approach to future investments and commitments.
Upcoming Events and Investor Relations
Coloplast is set to host a conference call to discuss its quarterly results in detail, providing stakeholders with insight and an opportunity for direct engagement. Interested parties are encouraged to register for this event to ensure participation during the Q&A session.
The company encourages investors and analysts to reach out to their dedicated teams for further information and clarifications. Contacts include:
Investors and Analysts
Anders Lonning-Skovgaard, Executive Vice President, CFO
Tel: +45 4911 1111
Aleksandra Dimovska, Vice President, Investor Relations
Tel: +45 4911 1800 / +45 4911 2458
Email: dkadim@coloplast.com
Kristine Husted Munk, Senior Manager, Investor Relations
Tel: +45 4911 1800 / +45 4911 3266
Email: dkkhu@coloplast.com
Simone Dyrby Helvind, Senior Manager, Investor Relations
Tel: +45 4911 1800 / +45 4911 2981
Email: dksdk@coloplast.com
Frequently Asked Questions
What is the organic growth rate for Coloplast in 9M 2024/25?
Coloplast achieved an organic growth rate of 7% for the nine months ended in 2024/25.
How did Coloplast's EBIT margin perform this quarter?
The EBIT margin reached 28%, which is an increase from the previous year's performance.
Which business segment saw the highest growth?
Voice and Respiratory Care led with a 9% growth rate, reflecting strong demand in its segments.
Are there any leadership changes at Coloplast?
Yes, there have been changes to the Executive Leadership Team to support the company’s strategic direction towards 2030.
When is the next investor conference call scheduled?
The conference call is scheduled for Tuesday, 19 August 2025, at 11.00 CEST.
About The Author
Contact Owen Jenkins privately here. Or send an email with ATTN: Owen Jenkins as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
